← Browse by Condition
Medical Condition

pancreatic adenosquamous carcinoma

Total Trials
1
Recruiting Now
1
Trial Phases
Phase 3
NCT07491445 Phase 3
Recruiting

Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma

Enrollment
900 pts
Location
United States
Sponsor
Revolution Medicines, Inc.
View Trial →